Vaccine Adjuvants Market

Market Overview:

The global vaccine adjuvants market size reached US$ 884 Million in 2022. Looking forward, IMARC Group expects the market to reach US$ 1,812 Million by 2028, exhibiting a growth rate (CAGR) of 12.4% during 2023-2028.

Vaccines contain weakened and dead germs that initiate the immune response and activate antigen presenting cells (APCs). This reaction helps the body increase its ability to induce long-term protection and safety against any infection. Vaccine adjuvants are compounds that improve this immunogenic reaction of the body against antigens that have insufficient immunostimulatory capabilities. Aluminum salts and MF59, an oil-in-water emulsion composed of squalene, are among the two common adjuvants that are feasible for human use.

Vaccine Adjuvants Market Trends:

The global vaccine adjuvants market is primarily driven by the rising prevalence of allergies and infectious diseases, including cancer, human immunodeficiency virus (HIV/AIDS), human papillomavirus (HPV) and tuberculosis. The need for advanced treatment options for existing and emerging fatal diseases has resulted in the development of vaccines that have long-lasting effects on immunization. For instance, key manufacturers have developed new adjuvants such as AS01, ISCOM & ISCOMMATRIX, and AS02, which are under clinical trials. Besides this, governments of various countries are taking initiatives for immunization and advancements in adjuvants for human use. They are also focusing on improving healthcare infrastructure and increasing investments for research and development (R&D) of new therapeutics. For example, market players are investing in the development of novel vaccine adjuvants as a potential solution against diseases caused by challenging pathogens, such as malaria and herpes, as well as for vulnerable populations that respond poorly to traditional vaccines, including older adults, neonates, and individuals with compromised immunity and comorbidities. Moreover, with the spread of the coronavirus disease (COVID-19) pandemic caused by SARS-CoV-2, there has been an increasing demand for effective and safe vaccine adjuvants. These factors are expected to provide a positive outlook for the market in the upcoming years.

Key Market Segmentation:

IMARC Group provides an analysis of the key trends in each sub-segment of the global vaccine adjuvants market report, along with forecasts at the global, regional and country level from 2023-2028. Our report has categorized the market based on product type, route of administration, diseases and application.

Breakup by Product Type:

• Adjuvant Emulsions
• Pathogen Components
• Particulate Adjuvants
• Combination Adjuvants
• Others
   

Breakup by Route of Administration:

• Oral
• Intramuscular
• Intranasal
• Subcutaneous
• Intradermal
• Others
   

Breakup by Diseases:

• Cancer
• Infectious Diseases
• Others
   

Breakup by Application:

• Research
• Commercial
   

Breakup by Region:

• North America
  • United States
  • Canada
• Asia-Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Indonesia
  • Others
• Europe
  • Germany
  • France
  • United Kingdom
  • Italy
  • Spain
  • Russia
  • Others
• Latin America
  • Brazil
  • Mexico
  • Others
• Middle East and Africa
   

Competitive Landscape:

The competitive landscape of the industry has also been examined along with the profiles of the key players being Adjuvance Tecchnologies Inc., Adjuvatis, Agenus Inc., Brenntag SE, Chemtrade Logistics Inc., CSL Limited, Croda International Plc, Invivogen, Novavax Inc., OZ Biosciences and Virometix AG.

Report Coverage: